ABSTRACT
This study was conducted between March 2020 and February 2021 to analyze anxiety and depression symptoms in 64 women with gestational trophoblastic disease (GTD) and 99 women who had miscarried. The Hospital Anxiety and Depression Scale (HADS) was applied by telephone three months after pregnancy loss. Multivariate analysis was performed using hierarchical logistic regression to evaluate associations between variables. Probable anxiety (HADS-A ≥ 8) and depression (HADS-D ≥ 8) were found in 53.1% and 43.8% of the GTD group and 49.5% and 39.4% of the miscarriage group, with no difference between the groups. Severe symptoms of anxiety (HADS-A 15-21) and depression (HADS-D 15-21) were found, respectively, in 12.5% and 4.7% of the GTD group and in 9.1% and 4.0% of the miscarriage group, also with no difference between the groups. Lack of partner support proved a risk factor for anxiety and depression, while poor education increased the risk of depression symptoms 3.43-fold following pregnancy loss. In conclusion, three months after pregnancy loss the frequency of anxiety and depression symptoms was similarly high in both groups, with poor education and lack of partner support being significant risk factors for the subsequent development of psychiatric morbidity.
Subject(s)
Abortion, Spontaneous , Gestational Trophoblastic Disease , Pregnancy , Female , Humans , Abortion, Spontaneous/epidemiology , Abortion, Spontaneous/psychology , Cross-Sectional Studies , Depression/psychology , Anxiety/etiology , Gestational Trophoblastic Disease/epidemiology , Gestational Trophoblastic Disease/psychologyABSTRACT
Abstract Objectives: to determine the frequency of stress, anxiety, and depression symptoms in symptomatic patients for COVID-19. To evaluate the associated factors involved in these variants. Methods: between May/June of 2020, it was conducted a prospective cross-section study with symptomatic participants for COVID-19 (n=300). It was applied an online questionnaire and the DASS-21 to evaluate the mental health of participants. Results: it was observed that 28.6%, 29.7% and 27% of the participants showed severe/extreme levels symptoms of stress, anxiety, and depression, respectively. The testing for COVID-19 application had constituted a protective factor for the development of psychiatric morbidity, once it had shown significant association in the low frequencies of severe/extreme depression [Odds Ratio (OR)]= 0.26; p=0.002) and stress (OR=0.39; p=0.01). Conclusion: individuals that are symptomatic for COVID-19 are a vulnerable group that may present high symptomatology for depression, anxiety, and stress. The identification of psychiatric morbidity frequency and its associated factors may contribute for the development of mental health strategies aiming at the prevention and mitigation of psychological impact in COVID-19 symptomatic population during the pandemic.
Resumo Objetivos: determinar a frequência de sintomas de estresse, ansiedade e depressão em pacientes sintomáticos para COVID-19 e avaliar os fatores associados. Métodos: entre maio / junho de 2020, foi realizado um estudo transversal prospectivo com participantes sintomáticos para COVID-19 (n = 300). Foi aplicado um questionário online e o DASS-21 para avaliar a saúde mental dos participantes. Resultados: observou-se que 28,6%, 29,7% e 27% dos participantes apresentaram sintomas graves/extremos para estresse, ansiedade e depressão, respectivamente. A realização do teste para a COVID-19 constituiu-se como fator de proteção para o desenvolvimento de sintomatologia psíquica, uma vez que mostrou associação significativa nas baixas frequências de depressão grave/extrema [odds ratio (OR)]= 0,26; p=0,002) e de estresse (OR=0,39; p=0,01). Conclusão: os indivíduos sintomáticos para COVID-19 constituem um grupo vulnerável que podem apresentar elevada sintomatologia para depressão, ansiedade e estresse. A identificação da frequência de morbidade psiquiátrica e seus fatores associados podem contribuir para o desenvolvimento de estratégias de saúde mental visando a prevenção e mitigação do impacto psicológico na população sintomática de COVID-19 durante a pandemia.